thereby producing insights that better represent the needs of all patients. "By leveraging advanced AI capabilities, we can ...

Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options.

A treatment of acute myeloid leukemia being developed by Sanofi (SNY) US Services was granted FDA orphan designation, according to a post to the agency’s website. Published first on TheFly – the ...

The announcement came in the build-up to an R&D presentation to investors that will be held in New York later today ... come under pressure. Sanofi CEO Paul Hudson All eyes are now on today ...

Robert is currently chief digital officer at the cruise line firm Viking Cruises and will join Sanofi on 15th June. His brief is to drive Sanofi’s digital, data and technology strategy ...

French healthcare company Sanofi has decided to halt work on its once praised breast cancer medication amcenestrant after a second failed clinical trial. A possible new coronavirus vaccine ...

Sanofi has returned with 300 million euros ($326 million) to set up a more permanent radioligand project. The new entity, which will operate under the Orano Med brand, will be focused on ...

“We understand the concerns parents face during RSV season, and we are dedicated to providing new solutions to protect all babies,” said Delphine Lansac, General Manager of Vaccines at Sanofi.

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

Global pharmaceutical company Sanofi is partnering with Healx, a U.K.-based clinical-stage biotech specializing in rare diseases, to use its artificial intelligence to identify novel rare disease ...

Sanofi is deepening its commitment to targeted radiation treatments for cancer with a €300 million equity investment in a new entity pursuing next-generation radioligand therapies. The new ...